JP2022524018A5 - - Google Patents

Info

Publication number
JP2022524018A5
JP2022524018A5 JP2021552750A JP2021552750A JP2022524018A5 JP 2022524018 A5 JP2022524018 A5 JP 2022524018A5 JP 2021552750 A JP2021552750 A JP 2021552750A JP 2021552750 A JP2021552750 A JP 2021552750A JP 2022524018 A5 JP2022524018 A5 JP 2022524018A5
Authority
JP
Japan
Prior art keywords
fusion protein
formula
sequence
formulas
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021552750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021498 external-priority patent/WO2020181235A1/en
Publication of JP2022524018A publication Critical patent/JP2022524018A/ja
Publication of JP2022524018A5 publication Critical patent/JP2022524018A5/ja
Priority to JP2025176328A priority Critical patent/JP2026016505A/ja
Withdrawn legal-status Critical Current

Links

JP2021552750A 2019-03-06 2020-03-06 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 Withdrawn JP2022524018A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025176328A JP2026016505A (ja) 2019-03-06 2025-10-20 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962814669P 2019-03-06 2019-03-06
US62/814,669 2019-03-06
US201962899504P 2019-09-12 2019-09-12
US62/899,504 2019-09-12
US202062962332P 2020-01-17 2020-01-17
US62/962,332 2020-01-17
PCT/US2020/021498 WO2020181235A1 (en) 2019-03-06 2020-03-06 Il-10 variant molecules and methods of treating inflammatory disease and oncology

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025176328A Division JP2026016505A (ja) 2019-03-06 2025-10-20 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Publications (2)

Publication Number Publication Date
JP2022524018A JP2022524018A (ja) 2022-04-27
JP2022524018A5 true JP2022524018A5 (cg-RX-API-DMAC7.html) 2023-04-26

Family

ID=72334859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552750A Withdrawn JP2022524018A (ja) 2019-03-06 2020-03-06 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
JP2025176328A Pending JP2026016505A (ja) 2019-03-06 2025-10-20 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025176328A Pending JP2026016505A (ja) 2019-03-06 2025-10-20 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Country Status (7)

Country Link
US (9) US10858412B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934681A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022524018A (cg-RX-API-DMAC7.html)
KR (1) KR20210139312A (cg-RX-API-DMAC7.html)
CN (2) CN114072164A (cg-RX-API-DMAC7.html)
CA (1) CA3132385A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020181235A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Il13を含む融合タンパク質
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
CN116322785A (zh) 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
CN112898436A (zh) * 2020-10-23 2021-06-04 广州医科大学附属肿瘤医院 一种具有靶向功能的鼠pd1和鼠il-15基因融合蛋白的表达及其应用
KR102792982B1 (ko) * 2021-05-28 2025-04-14 한양대학교 산학협력단 세포투과성 펩티드 및 이의 용도
EP4414381A4 (en) * 2021-11-02 2025-01-22 Guangdong Fapon Biopharma Inc. MONOMERIC FUSION PROTEIN OF IL-10 AND ITS USE
KR20240156653A (ko) * 2021-12-13 2024-10-30 데카 바이오사이언시즈, 인크. 다중-서브유닛 시토카인을 포함하는 이중 시토카인 융합 단백질
JP2024546999A (ja) * 2021-12-16 2024-12-26 デカ バイオサイエンシーズ, インコーポレイテッド Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー
AU2023225954A1 (en) 2022-02-22 2024-09-05 Deka Biosciences, Inc. Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins
CN114632156B (zh) * 2022-05-17 2022-08-16 中国人民解放军军事科学院军事医学研究院 Tim-3在预防、治疗或减轻疼痛中的应用
US20260174822A1 (en) * 2022-11-02 2026-06-25 Shattuck Labs, Inc. Fusion proteins for the treatment of nonalcoholic steatohepatitis
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
IL328577A (en) * 2023-11-24 2026-07-01 Medpacto Inc Fusion protein that specifically binds to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfβ) and its use
CN121108363A (zh) * 2024-06-12 2025-12-12 广东菲鹏制药股份有限公司 一种融合蛋白及其用途
CN119613546B (zh) * 2025-02-10 2025-05-13 细胞生态海河实验室 Il-10抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536170A (ja) * 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
EP2209805B1 (en) * 2007-10-30 2017-09-06 Philogen S.p.A. An antigen associated with rheumatoid arthritis
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
WO2012045334A1 (en) * 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
EP2903629B1 (en) * 2012-10-03 2019-07-10 Philogen S.p.A. Antibody conjugate for use in treating inflammatory bowel disease
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
BR112016016658A2 (pt) * 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3233920B1 (en) * 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
US10144768B2 (en) * 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation

Similar Documents

Publication Publication Date Title
JP2023534847A5 (cg-RX-API-DMAC7.html)
IL300062A (en) Dual fused cytokine proteins containing IL-10
RU2451689C2 (ru) Новые антипролиферативные антитела
Both et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections
JP2024546938A5 (cg-RX-API-DMAC7.html)
US9499619B2 (en) Polyclonal bispecific antibody compositions and method of use
JP2020036595A5 (cg-RX-API-DMAC7.html)
JP7164528B2 (ja) Pd-1に特異的に結合する可能な抗体及びその機能的断片
US20110275123A1 (en) Compositions and methods for generating antibodies
JP2025060802A5 (cg-RX-API-DMAC7.html)
JP2008543774A5 (cg-RX-API-DMAC7.html)
JP2021516976A5 (cg-RX-API-DMAC7.html)
IL313525A (en) Dual cytokine fusion proteins containing multisubunit cytokines
JP2022512915A5 (cg-RX-API-DMAC7.html)
Roselli et al. CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al.
JP2020522254A (ja) 骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用
JP2022033734A (ja) グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択
JP2024537804A5 (cg-RX-API-DMAC7.html)
JP2018527952A5 (cg-RX-API-DMAC7.html)
RU2016126488A (ru) Иммунотерапия рака
JP2025508882A5 (cg-RX-API-DMAC7.html)
JP2018518200A (ja) 多重特異性抗体プラットフォームおよびその関連方法
JP2022527994A (ja) 三重特異性結合性タンパク質、方法、およびその使用
JP2024546999A5 (cg-RX-API-DMAC7.html)
JP2023550419A5 (cg-RX-API-DMAC7.html)